Eglin Pharma Named a 2025 Shenzhen 'Seed Unicorn' Enterprise

On July 18, the 2025 China (Shenzhen) Unicorn Enterprise Conference, themed "New Quality Drive · Future Leadership," concluded successfully in Shenzhen. As a benchmark industry event for the development of new quality productivity, this year's conference attracted over a hundred unicorn companies and more than fifty representatives from financial investment institutions to gather and engage in in-depth discussions on the integration paths of cutting-edge technology and industry. The conference also重磅 released the Gazelle Enterprise and Unicorn Enterprise series of rankings.Evergreen Therapeutics Honored on the "2025 Shenzhen Seed Unicorn Enterprises" List。

This award was jointly granted by the Shenzhen Municipal Industry and Information Technology Bureau and the SME Service Bureau. After multiple rounds of evaluation procedures, the evaluation committee focused on assessing the founding team, product technology, market prospects, and capital recognition, selecting companies with "hardcore" technology and explosive growth potential from the enterprise pool to form the list. The "Shenzhen Unicorn and Gazelle Enterprise Research Report 2025" pointed out that the number of unicorn enterprises in Shenzhen increased significantly in 2024, with 143 seed unicorn enterprises mainly distributed in "hard tech" sectors such as artificial intelligence, robotics, integrated circuits, and clean energy. This award marks that Evergreen Therapeutics' technological innovation capabilities and commercial implementation potential have further gained dual recognition from policies and capital.

As a pioneer in China's AI clinical field, Evergreen Therapeutics has independently built an AI-powered drug R&D platform, covering key decision-making nodes throughout the drug lifecycle, including indication prioritization, pathway analysis and mechanism elucidation, and clinical trial prediction and optimization. Different from traditional R&D models, by employing AI technology-driven efficient solutions, the company can significantly shorten the new drug R&D cycle and reduce costs, successfully addressing the industry pain points of "low R&D efficiency and high failure rates." Currently, Evergreen Therapeutics has successfully obtained six IND approvals in the U.S., with over 60 global patent applications filed cumulatively.

In the field of commercial services, Evergreen Therapeutics, relying on an expert team led by several former FDA reviewers, provides clinical strategy formulation and international regulatory submission technical services to pharmaceutical companies in China. It has already helped dozens of pharmaceutical companies achieve regulatory milestones such as new drug IND and special policy submissions, with a 100% success rate for client IND applications. To further promote industry collaboration and innovation, the company will open its self-developed AI-based clinical trial protocol writing system, enhancing regulatory submission efficiency through technological empowerment and jointly building an open and efficient new ecosystem for pharmaceutical R&D.

In the future, Evergreen Therapeutics will adhere to the dual-driven strategy of "AI Clinical Technology + International Services," focusing on urgent clinical needs. While deeply cultivating its own drug development, the company will provide “one-stop” support to partners, helping them enter the global market with lower risks and at a faster pace, thereby realizing long-term value.